[go: up one dir, main page]

PE20081351A1 - Derivados de quinazolina como agentes anticancerigenos - Google Patents

Derivados de quinazolina como agentes anticancerigenos

Info

Publication number
PE20081351A1
PE20081351A1 PE2007001740A PE2007001740A PE20081351A1 PE 20081351 A1 PE20081351 A1 PE 20081351A1 PE 2007001740 A PE2007001740 A PE 2007001740A PE 2007001740 A PE2007001740 A PE 2007001740A PE 20081351 A1 PE20081351 A1 PE 20081351A1
Authority
PE
Peru
Prior art keywords
cancer agents
ethyl
amino
quinazoline derivatives
quinazolin
Prior art date
Application number
PE2007001740A
Other languages
English (en)
Inventor
Brian Aquila
Donald James Cook
Stephen Lee
Paul Lyne
Melissa Vasbinder
Haixia Wang
Craig Johnstone
David Alan Rudge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081351A1 publication Critical patent/PE20081351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE QUINAZOLINA DE FORMULA (I), DONDE R1 ES HALOGENO, NITRO, CIANO, OH, TRIFLUOROMETOXI, ENTRE OTROS; n ES UN ENTERO DE 0 A 4; R2 ES HALOGENO, AMINO, CARBAMOILO, CARBOXI, ENTRE OTROS; m ES UN ENTERO DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]ACETAMIDA, 4-(6-BROMOQUINAZOLIN-2-ILAMINO)-N-(2-(DIMETILAMINO)ETIL)BENCENSULFONAMIDA, 3-METOXI-N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]PROPANAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA B-RAF Y SON UTILES COMO AGENTES ANTICANCERIGENOS
PE2007001740A 2006-12-08 2007-12-07 Derivados de quinazolina como agentes anticancerigenos PE20081351A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86924106P 2006-12-08 2006-12-08
US98573207P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
PE20081351A1 true PE20081351A1 (es) 2008-11-26

Family

ID=39386079

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001740A PE20081351A1 (es) 2006-12-08 2007-12-07 Derivados de quinazolina como agentes anticancerigenos

Country Status (5)

Country Link
AR (1) AR064208A1 (es)
CL (1) CL2007003557A1 (es)
PE (1) PE20081351A1 (es)
TW (1) TW200829566A (es)
WO (1) WO2008068507A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
KR20090092287A (ko) * 2006-12-22 2009-08-31 노파르티스 아게 Ｐｄｋ１ 억제를 위한 퀴나졸린
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
CA2730774C (en) 2008-07-31 2016-09-13 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
WO2010092041A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US10554578B2 (en) 2015-06-30 2020-02-04 British Telecommunications Public Limited Company Quality of service management in a network
EP4219746B1 (en) 2016-09-02 2024-12-18 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
CN111170986A (zh) * 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025092989A1 (zh) * 2023-11-03 2025-05-08 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037285A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
AR064208A1 (es) 2009-03-18
WO2008068507A3 (en) 2008-07-31
CL2007003557A1 (es) 2008-08-01
WO2008068507A2 (en) 2008-06-12
TW200829566A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
PE20081351A1 (es) Derivados de quinazolina como agentes anticancerigenos
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20120814A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
PE20090837A1 (es) Nuevos compuestos quimicos
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
IL177280A (en) Monohydrate crystal of 2-aminothiazole-5-aromatic carboxamide, process for its preparation, its pharmaceutical composition and its use in the preparation of medicine
NZ593295A (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
EA200870461A1 (ru) Производные лактама циклогексилимидазола в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20070113A1 (es) Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb
PE20110584A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal